Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

This completed Phase III feasibility trial (n=32) investigated the potential of ketamine to prevent postoperative depressive (PPD) symptoms in neurosurgical patients with a history of depression.

Conducted by the Washington University School of Medicine, the trial followed a randomised, placebo-controlled, double-blinded, parallel design. Patients received either a ketamine infusion or normal saline post-surgery and were assessed for depressive symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS). The study aimed to assess the feasibility of conducting a full-scale phase III trial.

The primary outcomes included the fraction of approached patients who enrolled and were randomised, the fraction of randomised patients who completed the study infusion, and the fraction of randomised patients with MADRS scores at specified time points. Secondary outcomes included depressive symptoms and delta sleep ratio. The trial commenced on April 25, 2022, with a primary completion date of March 8, 2023. Recruitment took place at Washington University in St. Louis School of Medicine/Barnes-Jewish Hospital, Missouri, United States.

Status Completed
Results Published No
Start date 25 April 2022
End date 08 March 2023
Phase Phase III
Design Blinded
Type Interventional
Generation First
Participants 32
Sex All
Age 18- 99
Therapy No

Trial Details

This protocol describes a feasibility trial that will evaluate the feasibility of conducting a full-scale phase 3 trial testing the hypothesis that a postoperative sustained, low-dose ketamine infusion can prevent postoperative depressive symptoms when administered to a targeted population of neurosurgical patients with a history of depression.

NCT Number NCT05233566

Sponsors & Collaborators

Washington University School of Medicine
Located in St. Louis Missouri, researchers at the Washington University School of Medicine have conducted a number of studies with psychedelics inlcuding ketamine, psilocybin and nitrous oxide.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.